mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes.
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by SDS-PAGE. > 90 % as determined by SEC-MALS.
ELISA
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2), SARS CoV-2 Alpha
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 90 % as determined by SDS-PAGE and Coomassie blue staining.
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2), SARS CoV-2 Delta
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 90 % as determined by SDS-PAGE and Coomassie blue staining.
ELISA, WB
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by SDS-PAGE. > 90 % as determined by SEC-MALS.
ELISA
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ELISA, WB
SARS-CoV-2 S
Origine: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ELISA, WB
Dernières publications pour nos SARS-CoV-2 Spike Protéines
Gao, Yang, Dong, Tang, Cao, Ding, Zhu, Bai, Xia, Zhu, Zhao, Peng, Xu, Zhang: "A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV." dans: Frontiers in immunology, Vol. 15, pp. 1473428, (2024) (PubMed).
Yang, Liu, Jiang, Zhang, Fu, Li, Hu, Yuan: "Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells." dans: Vaccine, Vol. 42, Issue 6, pp. 1259-1267, (2024) (PubMed).
Mazunina, Gushchin, Bykonia, Kleymenov, Siniavin, Kozlova, Mukasheva, Shidlovskaya, Kuznetsova, Usachev, Zlobin, Burtseva, Ivanov, Logunov, Gintsburg: "Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models." dans: Vaccines, Vol. 12, Issue 11, (2024) (PubMed).
Wu, Cong, Wei, Hu, Sun, Ran, Liao, Zheng, Ye: "A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern." dans: International journal of nanomedicine, Vol. 18, pp. 5781-5795, (2023) (PubMed).
Payam, Funari, Scamarcio, Bhalla: "Sensing Dynamically Evolved Short-Range Nanomechanical Forces in Fast-Mutating Single Viral Spike Proteins." dans: Small science, Vol. 3, Issue 8, pp. 2300029, (2023) (PubMed).
Erickson, Logsdon, Rhea, Hansen, Holden, Banks, Smith, German, Farr, Morley, Weaver, Hirsch, Kovac, Kontsekova, Baumann, Omer, Raber: "Blood-brain barrier penetration of non-replicating SARS-CoV-2 and S1 variants of concern induce neuroinflammation which is accentuated in a mouse model of Alzheimer's disease." dans: Brain, behavior, and immunity, Vol. 109, pp. 251-268, (2023) (PubMed).
Meng, Zha, Zhou, Cao, Jiang, Zhu, Li, Lu, Zhang, Yang, Feng, Gu, Tang, Jiang, Li, Lavillette, Zhang: "A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy." dans: PLoS pathogens, Vol. 19, Issue 1, pp. e1011085, (2023) (PubMed).